首页>投融资
Epic Sciences
G轮
Epic Sciences Inc is a developer of liquid biopsy diagnostics to guide therapy selection and monitor disease progression to personalize the treatment and management of prostate and breast cancer.In April 2023, Epic Sciences Inc had completed $24 million Series G and $43 million Series F financing.In June 2022, Epic Sciences Inc had completed a $43 million first close of its Series F financing
基本信息
-
公司全称Epic Sciences Inc
-
类型液体活检及癌症治疗技术研发商
-
产业领域试剂/耗材、器械/设备
-
公司人数101~500人
-
地址9381 Judicial Dr Ste 200 SAN DIEGO CALIFORNIA 92121-3832; US; Telephone: +18583566610;
-
联系电话858-356-6610
-
邮箱info@epicsciences.com
-
成立时间2008-01-01
投融资
-
2023-04-15G轮2400万美元DOMAINBlue Ox Healthcare PartnersDeerfieldArsenal Capital PartnersLabCorp Venture Fund
-
2022-06-01F轮4300万美元Blue Ox Healthcare PartnersDeerfieldArsenal Capital PartnersLabCorp Venture Fund
-
2018-09-12E轮5200万美元Alexandria Venture InvestmentsDOMAINBlue Ox Healthcare PartnersDeerfieldSabby ManagementVarian Medical SystemsViventuresAltos Capital Partners
-
2017-04-28D轮4000万美元Sabby Capital
-
2015-06-01债权融资1500万美元美国硅谷银行
-
2014-07-30C轮3000万美元Pfizer VenturesRoche Venture FundDOMAINArcus Ventures
-
2012-11-03B轮1300万美元DOMAINReach Tone LimitedRMI PartnersAltos Capital Partners弘励创投
- 加载更多
相关投融资企业
B轮
星辰海医疗成立于2020年10月，是一家专注于内窥镜介入诊疗业务的医疗科技公司，旨在向全球提供涵盖泌尿、呼吸、消化等科室的内窥镜介入诊疗整体解决方案，让疾病更早被发现，让患者更好被治疗。内窥镜诊疗是非血管微创介入的重要组成部分，广泛分布于消化科、泌尿科、呼吸、耳鼻喉科、普外科以及妇科等。
D轮
Cytovale是一个由生物学家，数据科学家和工程师组成的团队，致力于开发机械生物标志物以改善人类健康。 Cytovale的新型微流体平台允许 Cytovale,Inc探测单个细胞以量化疾病的机械特征。 Cytovale首先将其应用于败血症，这种疾病的早期检测可显着改善患者预后并降低治疗成本。
未公开
Billiontoone Inc is a developer of a molecular counter platform intended to improve the resolution of cell-free DNA testing. The company's prenatal testing procedure focuses on quantitative biology and statistical learning methods to optimize the signal-to-noise ratio and detect single-gene disorders, enabling expecting mothers to detect disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a simple blood test.In December 2022, Billiontoone Inc announces it has secured an additional $48.5 million of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to $35 million With this additional funding, gross proceeds will reach $280 million.In March 2022, BillionToOne Inc closed an oversubscribed Series C funding round of $125 million with premier global investors
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息